Abstract:
The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.
Abstract:
An on-line click wrap electronic agreement that a user must agree to prior to being registered as a volunteer and considered as a potential candidate in a clinical trial or research study. The agreement authorizes the release of the end user's medical and/or personal information to representatives of the clinical trials and research studies for which the volunteer may be considered as a potential candidate. After receiving the end user's consent to the click wrap agreement an electronic survey form is generated by a secure server and displayed at the end user's computer terminal. Responses by the end user to the survey form are kept secure as much as possible while being transmitted from the computer terminal across the network to the server and while stored and accessed only by authorized personnel at the central office.
Abstract:
A method, executed by a server, for providing answers on one or more topics from a set of experts on each topic to questions posed by users. Users can direct questions to one or more specific experts, who in turn can answer the questions, refer the questions to other experts, or both. The server automatically organizes and stores questions and answers in various fora. An administrator can take advantage of the design of the system to create or change a forum without having to write or change low-level code.
Abstract:
Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.
Abstract:
The present invention relates to αvβ8 antagonists, anti-αvβ8 antibodies or immunoconjugates for reducing TGFβ activation in an individual. Further provided are compositions comprising one of the αvβ8 antagonists, anti-αvβ8 antibodies or immunoconjugates, methods for using the compositions, and related subject matter.
Abstract:
The present invention relates to a molecular structure characterised in that said structure includes at least one amino acid sequence selected from: SEQ. ID NO.: 1, SEQ. ID NO.: 2, SEQ. ID NO.: 3, SEQ. ID NO.: 4, SEQ. ID NO.: 5, SEQ. ID NO.: 6, SEQ. ID NO.: 7, SEQ. ID NO.: 8, SEQ. ID NO.: 9, SEQ. ID NO.: 10, SEQ. ID NO.: 11, SEQ. ID NO.: 12, SEQ. ID NO.: 13, SEQ. ID NO.: 14, SEQ. ID NO.: 15, SEQ. ID NO.: 16, SEQ. ID NO.: 17, SEQ. ID NO.: 18, SEQ. ID NO.: 19, SEQ. ID NO.: 20, SEQ. ID NO.: 21, SEQ. ID NO.: 22, SEQ. ID NO.: 23, SEQ. ID NO.: 24, SEQ. ID NO.: 25, SEQ. ID NO.: 26, SEQ. ID NO.: 27, SEQ. ID NO.: 28, SEQ. ID NO.: 29, SEQ. ID NO.: 30, SEQ. ID NO.: 31, SEQ. ID NO.: 32, SEQ. ID NO.: 33, SEQ. ID NO.: 34, SEQ. ID NO.: 35, SEQ. ID NO.: 36, said amino acid sequence corresponding to an antigen complementarity determining region (CDR) of the variable domain of the heavy chain (CDR-H) or the light chain (CDR-L) of an antibody targeting the human transferrin receptor (TfR). The present invention also relates to a pharmaceutical composition including a therapeutically effective amount of at least one molecular structure as defined in the present application, combined with a pharmaceutically acceptable carrier.
Abstract translation:本发明涉及分子结构,其特征在于所述结构包括至少一个选自以下的氨基酸序列:SEQ。 编号:1,SEQ。 编号:2,SEQ。 编号:3,SEQ。 编号:4,SEQ。 编号:5,SEQ。 编号:6,SEQ。 SEQ ID NO:7,SEQ。 SEQ ID NO:8,SEQ。 编号:9,SEQ。 编号:10,SEQ。 编号:11,SEQ。 SEQ ID NO:12,SEQ。 SEQ ID NO:13,SEQ。 SEQ ID NO:14,SEQ。 编号:15,SEQ。 编号:16,SEQ。 编号:17,SEQ。 编号:18,SEQ。 编号:19,SEQ。 SEQ ID NO:20,SEQ。 编号:21,SEQ。 编号:22,SEQ。 编号:23,SEQ。 SEQ ID NO:24,SEQ。 编号:25,SEQ。 编号:26,SEQ。 编号:27,SEQ。 编号:28,SEQ。 编号:29,SEQ。 SEQ ID NO:30,SEQ。 编号:31,SEQ。 编号:32,SEQ。 编号:33,SEQ。 编号:34,SEQ。 编号:35,SEQ。 SEQ ID NO:36,所述氨基酸序列对应于针对人转铁蛋白受体的抗体的重链(CDR-H)或轻链(CDR-L)的可变结构域的抗原互补决定区(CDR) (TfR)。 本发明还涉及药物组合物,其包含治疗有效量的至少一种如本申请中所定义的分子结构与药学上可接受的载体组合。
Abstract:
Antibodies that bind to botulinum neurotoxin(s) are disclosed herein, as well as related compositions and methods of use. The present disclosure provides antibodies that specifically bind a Botulinum neurotoxin (BoNT) and inhibit the activity of BoNT in cleavage of its substrate.
Abstract:
This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
Abstract:
This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
Abstract:
This invention provides novel prostate cancer specific internalizing human antibodies. The antibodies are useful by themselves to prevent growth and/or proliferation of prostate cancer cells. The antibodies can also be formulated as chimeric molecules to direct an effector (e.g. a cytotoxin, an imaging reagent, a drug, etc.) to a prostate tumor site.